Smith Group Asset Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Smith Group Asset Management’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-36,250	Closed	-$451K	–	492
2016 Q4	$451K	Hold	36,250	–	–	0.01%	194
2016 Q3	$496K	Hold	36,250	–	–	0.01%	181
2016 Q2	$268K	Buy	+36,250	New	+$272K	0.01%	224

Other funds holding ARIA

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Smith Group Asset Management's ARIA Position: Q1 2017 in Review

Smith Group Asset Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 36,250 shares — an estimated $451K sold.

Smith Group Asset Management first reported a position in ARIA in Q2 2016 and held it in 3 quarters. The position peaked at $496K in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

Smith Group Asset Management reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Smith Group Asset Management sold 36,250 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $451K.
Smith Group Asset Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2016 and held it in 3 quarters.
Smith Group Asset Management's Ariad Pharmaceuticals Inc position peaked at $496K in Q3 2016.
1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Smith Group Asset Management's 13F filing for Q1 2017, filed 4 May 2017.